{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:23:01Z","timestamp":1778901781253,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.transci.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T21:45:17Z","timestamp":1375479917000},"page":"295-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload"],"prefix":"10.1016","volume":"49","author":[{"given":"Serdar","family":"Sivgin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Baldane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah","family":"Akyol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer","family":"Keklik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Kurnaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Pala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokmen","family":"Zararsiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2013.07.004_b0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bmt.1703570","article-title":"Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation","volume":"29","author":"Altes","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/bmt.2008.262","article-title":"Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation","volume":"42","author":"Pullarkat","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbmt.2008.11.012","article-title":"Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Kataoka","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0020","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with \u03b2-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.004_b0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200725040-00005","article-title":"Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients US healthcare system perspective","volume":"25","author":"Delea","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.transci.2013.07.004_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1634\/theoncologist.2008-0154","article-title":"Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy","volume":"14","author":"Jabbour","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.transci.2013.07.004_b0035","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2010-01-261289","article-title":"EPIC study investigators. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial","volume":"116","author":"Lee","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.004_b0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematol"},{"key":"10.1016\/j.transci.2013.07.004_b0045","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.004_b0050","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00277-011-1358-1","article-title":"Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT)","volume":"91","author":"Sivgin","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2013.07.004_b0055","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.004_b0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2008.08.009","article-title":"Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma","volume":"14","author":"Mahindra","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0065","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/sj.bmt.1702447","article-title":"Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview","volume":"25","author":"Blijlevens","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bmt.2009.77","article-title":"Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation","volume":"44","author":"Mahindra","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0891-5849(94)E0145-9","article-title":"Sequential changes in serum iron and ferritin in patients undergoing high dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity","volume":"18","author":"Gordon","year":"1995","journal-title":"Free Rad Biol Med"},{"key":"10.1016\/j.transci.2013.07.004_b0080","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1128\/IAI.73.9.5493-5503.2005","article-title":"The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence","volume":"73","author":"Hissen","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.transci.2013.07.004_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/jcp.48.3.223","article-title":"Iron metabolism and fungal infections in patients with haematological malignancies","volume":"48","author":"Iglesias-Osma","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.transci.2013.07.004_b0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/500934","volume":"42","author":"Cordonnier","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.transci.2013.07.004_b0095","first-page":"206","article-title":"Pretransplant iron overload may be associated with increased risk of invasive fungal pneumonia (IFP) in patients that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT)","volume":"1473\u20130502","author":"Sivgin","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2013.07.004_b0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.bmt.1705340","article-title":"Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients","volume":"37","author":"Miceli","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1701885","article-title":"Mucormycosis in allogeneic bone marrow recipients: report of five cases and review of the role of iron overload in the pathogenesis","volume":"24","author":"Maertens","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0091270003253350","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.transci.2013.07.004_b0115","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once daily oral chelating agent, in pediatric patients with thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2013.07.004_b0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","article-title":"Relative response of patients with myelodysplastic syndromes and other transfusion- dependent anaemias to deferasirox (ICL670): a 1-year prospective study","volume":"80","author":"Porter","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2013.07.004_b0125","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2013.07.004_b0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbmt.2005.09.012","volume":"12","author":"Rizzo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2013.07.004_b0135","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2012-02-412692","article-title":"Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study","volume":"120","author":"Taher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transci.2013.07.004_b0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bmt.2009.88","article-title":"Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children","volume":"44","author":"Lee","year":"2009","journal-title":"Bone Marrow Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213002310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050213002310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:35:02Z","timestamp":1715816102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050213002310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1473050213002310"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2013.07.004","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}